This protocol addresses hereditary hemochromatosis in patients presenting with haemochromatosis arthropathy specifically affecting the 2nd and 3rd metacarpophalangeal joints and ankles — a pattern characterised by a younger age of onset than typical osteoarthritis, exuberant osteophytes, and rapid progression to cartilage loss.
Haemochromatosis arthropathy does not respond to phlebotomy and can develop even on maintenance therapy. The pattern of joint involvement — 2nd and 3rd metacarpophalangeal joints and ankles — is a recognisable feature of this condition, and its clinical course may differ meaningfully from non-haemochromatosis arthropathy.
Management involves a combination of agents targeting pain and inflammation alongside physiotherapy. The full structured regimen — including the complete sequence of interventions and further therapeutic options — is available via the link below.
Haemochromatosis arthropathy does not respond to phlebotomy and can develop on maintenance therapy.
The joint disease in haemochromatosis is similar to osteoarthritis but is associated with a younger age of onset; haemochromatosis arthropathy typically affects the 2nd and 3rd metacarpophalangeal joints and ankles, and is characterised by exuberant osteophytes and rapid progression to cartilage loss.
Treatment is limited to analgesics and non-steroidal anti-inflammatory agents, physiotherapy and ultimately orthopaedic procedures including joint replacement.
DOI: 10.1016/j.jhep.2022.03.033
View source ↗